Clik here to view.
Adamis Pharma’s EpiPen alternative succeeds in human factors study
Adamis Pharmaceuticals (NSDQ:ADMP) has positioned its emergency allergy treatment as a cheaper alternative to Mylan‘s (NSDQ:MYL) EpiPen device. The company has also set out to prove that its...
View ArticleClik here to view.
Clearside Biomedical floats $75m public offering
Clearside Biomedical (NSDQ:CLSD) plans to offer $75 million in shares of its common stock in an underwritten public offering. The Alpharetta, Ga.-based company is slated to use the funds to prepare and...
View ArticleClik here to view.
Sen. McCaskill: Teva is “stonewalling” Senate investigation into opioid crisis
Sen. Claire McCaskill (D-Mo.) said that Teva Pharmaceuticals (NYSE:TEVA) is “stonewalling” a Senate probe into the the role that opioid manufacturers have in the nation’s opioid crisis. In the...
View ArticleClik here to view.
Delcath inks supply deal with Tillomed Laboratories in Europe
Delcath Systems (NSDQ:DCTH) said today that it inked a commercial supply deal with Tillomed Laboratories in Europe. According to the deal, Tillomed Labs is slated to provide Delcath with melphalan –...
View ArticleClik here to view.
Valeritas takes on multiple daily insulin injections with wearable V-Go device
There are millions of Americans with Type II diabetes and many of them take multiple daily injections of insulin, using two injection pens – one for mealtime insulin and one for insulin throughout the...
View ArticleClik here to view.
Facing legal woes and SEC probe, Ocular Therapeutix posts mixed Q4
Shares in Ocular Therapeutix (NSDQ:OCUL) rose this morning after the company beat expectations on Wall Street with its fourth quarter earnings, but missed analysts’ sales estimates. The company is...
View ArticleClik here to view.
Senate bill looks to block tribal patent deals with pharma
Months after Allergan (NYSE:AGN) struck a controversial patent deal with a Native American tribe in New York, lawmakers are angling to make sure that it can’t happen again. Sens. Tom Cotton (R-Ar),...
View ArticleClik here to view.
Clearside Biomedical prices $85m underwritten offering
Clearside Biomedical (NSDQ:CLSD) priced 6,538,462 shares of its common stock at $13.00 apiece in an $85 million underwritten public offering that’s expected to close early next week. The Alpharetta,...
View ArticleClik here to view.
Insulet nabs spot as in-network provider with UnitedHealthcare
Insulet (NSDQ:PODD) and UnitedHealthcare (NYSE:UNH) inked a new network relationship last week, giving people enrolled in UnitedHealthcare’s commercial and Medicaid plans in-network coverage for...
View ArticleClik here to view.
MiMedx wins FDA regenerative med status for AmnioFix
MiMedx (NSDQ:MDXG) won regenerative medicine advanced therapy status from the FDA for its injectable osteoarthritis drug, AmnioFix, the company announced this week. The U.S. regulatory watchdog told...
View ArticleClik here to view.
Anika CEO retires after two decades; president assumes corner office |...
Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July...
View ArticleClik here to view.
Intec Pharma partners for manufacture of ‘accordion pill’ for Parkinson’s...
Intec Pharma (NSDQ:NTEC) plans to partner with LTS to manufacture the company’s lead product candidate – an oral pill for Parkinson’s disease formulated with Intec’s “Accordion Pill” drug delivery...
View ArticleClik here to view.
The company behind Narcan looks toward a treatment for fentanyl overdoses
Despite growing attention from lawmakers and doctors, the opioid crisis is not slowing up in the U.S. A new report published last week by the Centers for Disease Control and Prevention showed that...
View ArticleClik here to view.
Controversial “right to try” bill fails in the House
A controversial bill that would grant terminal patients access to experimental therapies failed yesterday in the House. Although the “right to try” effort didn’t muster up enough votes to send it to...
View ArticleClik here to view.
Clearside Biomedical posts Street-beating Q4, full year results
Shares in Clearside Biomedical (NSDQ:CLSD) fell today even though the biopharmaceutical company topped sales and earnings estimates on Wall Street with its fourth quarter and full year results. The...
View ArticleClik here to view.
Glooko touts patient outcomes for remote diabetes care tech
Glooko touted data today from a six-month pilot program that evaluated the company’s remote diabetes management technology for people with Type II diabetes. The pilot, which spanned from April until...
View ArticleClik here to view.
Inovio Pharmaceuticals logs Q4 earnings, sales beat
Inovio Pharmaceuticals (NSDQ:INO) topped sales and earnings estimates on Wall Street yesterday with its fourth quarter and full year results. The Plymouth Meeting, Pa.-based company posted a net loss...
View ArticleClik here to view.
Organogenesis launches new sizing option for PuraPly wound care device
MIT-spinoff Organogenesis announced today that its PuraPly antimicrobial wound care device is now available in a 1.6-cm disc size. The Canton, Mass.-based company’s PuraPly AM product includes a...
View ArticleClik here to view.
Bellerophon Therapeutics misses EPS estimates in Q4
Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed earnings expectations on Wall Street with its fourth-quarter and full-year results. The Warren, N.J.-based...
View ArticleClik here to view.
Meet the insulin-makers and device companies developing smart insulin pens
The global market for connected insulin pens could be worth up to $123 million by 2023, according to a report published this year by Research & Markets. Insulin pens, designed for people who...
View Article